Spravato is a medication recently approved for the treatment of depression that has not responded adequately to other more standard medications. It has a new and novel mechanism of action.
Spravato is only dispensed and administered to patients in a medically supervised healthcare setting that will monitor these patients. It is given as an intra-nasal spray. The standard protocol is twice weekly treatments for one month followed by weekly sessions for the next month. Additional treatment after this would be determined on a case by case basis.
Please click HERE for additional information.